ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025

ABVC BioPharma, Inc. reported substantial financial growth in its third quarter 2025 results, with licensing revenue increasing 230% year-over-year and total assets growing 181% since December 2024. The clinical-stage biopharmaceutical company, which develops therapeutic solutions for central nervous system disorders, ophthalmology, and oncology/hematology indications, recognized approximately $1.28 million in licensing revenue for Q3 2025 compared to $0.39 million for the same period in 2024.

The company's total assets reached $21.18 million as of September 30, 2025, up from $7.54 million at the end of 2024. This significant expansion was driven primarily by strategic real-asset investments in Taiwan, where property and equipment grew approximately 2,100% to $12.06 million from just $0.51 million at year-end 2024. These developments signal ABVC's transition toward a more asset-intensive business model while maintaining its focus on licensing and partnerships.

During the third quarter, ABVC completed two major land acquisitions in Taiwan totaling approximately $11 million. AiBtl BioPharma Inc., a subsidiary, acquired property in Puli, Nantou for $7.67 million to develop a plant factory for botanical raw materials and new drug substance research. The parent company invested $3.3 million in Longtan, Taoyuan for agricultural research and development and active pharmaceutical ingredient cultivation. These investments, combined with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the company's Asia-based production and research capabilities.

The company's global dual-core operational structure continues to develop, with Silicon Valley focusing on innovation and clinical development through its BioKey platform, while Taiwan supports manufacturing and development activities. This strategic approach allows ABVC to leverage the technological expertise of Silicon Valley while benefiting from Taiwan's manufacturing infrastructure and research capabilities. The company maintains multiple licensing agreements covering CNS, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the third-quarter results reflect continued progress in both licensing revenue and asset development activities. The company remains focused on executing strategic priorities to create sustainable long-term value for shareholders. Investors can access detailed financial information through the Securities and Exchange Commission's website at https://www.sec.gov, where the company files its regular financial disclosures.

This financial performance demonstrates ABVC's successful execution of its growth strategy amid increasing competition in the biopharmaceutical sector. The substantial increase in physical assets represents a strategic shift that could enhance the company's research capacity and manufacturing capabilities, potentially accelerating drug development timelines. For the broader biotech industry, ABVC's model of combining Silicon Valley innovation with Asian manufacturing infrastructure offers a template for other companies seeking to optimize global operations while controlling costs.

The company's progress is particularly significant given the challenges facing clinical-stage biopharmaceutical companies, including difficulties in obtaining financing, manufacturing scale-up challenges, and regulatory hurdles. ABVC's ability to grow both licensing revenue and physical assets simultaneously suggests effective management of both immediate revenue streams and long-term strategic investments. This balanced approach could position the company favorably for future partnerships and clinical advancements across its pipeline of six drugs and one medical device currently under development.